Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.

[1]  Daniel F Chen,et al.  Oncologist use of the Adjuvant! model for risk communication: a pilot study examining patient knowledge of 10-year prognosis , 2009, BMC Cancer.

[2]  L. Tafra,et al.  Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study. , 2009, Journal of the American College of Surgeons.

[3]  Angela Fagerlin,et al.  Improving understanding of adjuvant therapy options by using simpler risk graphics , 2008, Cancer.

[4]  Bernard Rachet,et al.  Cancer survival in five continents: a worldwide population-based study (CONCORD). , 2008, The Lancet. Oncology.

[5]  L. Esserman,et al.  Risk communication with patients with breast cancer: cautionary notes about printing Adjuvant! estimates. , 2008, The Lancet. Oncology.

[6]  S. Pocock,et al.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2008, Journal of clinical epidemiology.

[7]  L. V. van't Veer,et al.  Clinical application of the 70-gene profile: the MINDACT trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Douglas G Altman,et al.  [The Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] statement: guidelines for reporting observational studies]. , 2007, Gaceta sanitaria.

[9]  P. Ravdin,et al.  A decision aid to assist in adjuvant therapy choices for breast cancer , 2006, Psycho-oncology.

[10]  Marc Buyse,et al.  Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial , 2006, Nature Clinical Practice Oncology.

[11]  L. Clegg,et al.  Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Zhao Chen,et al.  Ethnicity and breast cancer: factors influencing differences in incidence and outcome. , 2005, Journal of the National Cancer Institute.

[13]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[14]  Karen A Gelmon,et al.  Population-based validation of the prognostic model ADJUVANT! for early breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  M. Coleman,et al.  Breast carcinoma survival in Europe and the United States , 2004, Cancer.

[16]  A. McTiernan,et al.  Weight loss in breast cancer patient management. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Gelber,et al.  Meeting highlights: international consensus panel on the treatment of primary breast cancer. , 2002, Journal of the National Cancer Institute.

[18]  R. Gelber,et al.  Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Robert J. Mayer,et al.  National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. , 2001, Journal of the National Cancer Institute.

[20]  P. Ravdin,et al.  Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Schemper,et al.  Predictive Accuracy and Explained Variation in Cox Regression , 2000, Biometrics.

[22]  B. Gusterson,et al.  Role of immunohistochemical detection of lymph-node metastases in management of breast cancer , 1999, The Lancet.

[23]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[24]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[25]  F. Harrell,et al.  Prognostic/Clinical Prediction Models: Multivariable Prognostic Models: Issues in Developing Models, Evaluating Assumptions and Adequacy, and Measuring and Reducing Errors , 2005 .

[26]  R. Gelber,et al.  Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. , 1995, Journal of the National Cancer Institute.

[27]  R. Blamey,et al.  A prognostic index in primary breast cancer. , 1982, British Journal of Cancer.

[28]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[29]  I. Ellis,et al.  The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.

[30]  K. Zedeler,et al.  Medullary carcinoma of the breast, prognostic importance of characteristic histopathological features evaluated in a multivariate Cox analysis. , 1994, European journal of cancer.